U/S-guided Continuous Quadratus Lumborum Block III in Percutaneous Nephrolithotomy
NCT ID: NCT04800302
Last Updated: 2022-07-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
45 participants
INTERVENTIONAL
2021-06-10
2022-06-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ultrasound Guided Anterior Quadratus Lumborum Block
NCT03425162
Paravertebral Block Versus Erector Spinae Plain Block In Percutaneous Nephrolithotomy
NCT04998435
Comaprison Between QLB and ESPB in Patients for PCNL Operation
NCT04277611
Analgesic Efficacy of Ultrasound Guided Quadratus Lumborum Block During ESWL
NCT03080363
Quadratus Lumborum Block Versus Erector Spinae Plane Block in Extracorporeal Shock Wave Lithotripsy(ESWL)
NCT05937256
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Continuous QLB group
U/S-guided continous QLB III
Continous Quadratum Lumborum Block III
Continuous infusion of Bupivacaine 0.125 % at a rate of 0.1 ml/kg/hr (not exceeding 12 ml/hour), infused through a catheter inserted in the plane between quadratus lumborum \& psoas major muscles with ultrasound guidance.
Single dose Quadratum Lumborum Block III
Single injection of a mixture solution of 20 ml Bupivacaine 0.5% + 10 ml Lidocaine 2%, injected through a needle inserted at the posterior aspect of the quadratus lumborum muscle between it and erector spinae muscle with ultrasound guidance.
Intra-venous Morphine
Intra-venous Morphine \[0.1 mg/kg\] as rescue analgesic shots when the Visual Analogue Score (VAS) for pain exceeds 4.
Single dose QLB group
U/S-guided single dose QLB III
Single dose Quadratum Lumborum Block III
Single injection of a mixture solution of 20 ml Bupivacaine 0.5% + 10 ml Lidocaine 2%, injected through a needle inserted at the posterior aspect of the quadratus lumborum muscle between it and erector spinae muscle with ultrasound guidance.
Intra-venous Morphine
Intra-venous Morphine \[0.1 mg/kg\] as rescue analgesic shots when the Visual Analogue Score (VAS) for pain exceeds 4.
Morphine group
IV Morphine
Intra-venous Morphine
Intra-venous Morphine \[0.1 mg/kg\] as rescue analgesic shots when the Visual Analogue Score (VAS) for pain exceeds 4.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Continous Quadratum Lumborum Block III
Continuous infusion of Bupivacaine 0.125 % at a rate of 0.1 ml/kg/hr (not exceeding 12 ml/hour), infused through a catheter inserted in the plane between quadratus lumborum \& psoas major muscles with ultrasound guidance.
Single dose Quadratum Lumborum Block III
Single injection of a mixture solution of 20 ml Bupivacaine 0.5% + 10 ml Lidocaine 2%, injected through a needle inserted at the posterior aspect of the quadratus lumborum muscle between it and erector spinae muscle with ultrasound guidance.
Intra-venous Morphine
Intra-venous Morphine \[0.1 mg/kg\] as rescue analgesic shots when the Visual Analogue Score (VAS) for pain exceeds 4.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Scheduled for percutaneous nephrolithotomy (PCNL).
Exclusion Criteria
* Coagulation disorders.
* Skin lesions or infection at site of needle insertion.
* Known allergy to local anesthetics or opioids.
* Patients suffering from neurological or mental disease.
* Procedure turned into open stone surgery.
* Failure of identification by U/S.
* Urinary tract malignancies.
* Opioid consumption 48 hours before the operation.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nazmy Edward Seif
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nazmy Edward Seif
Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sherif A Embaby, MSc
Role: PRINCIPAL_INVESTIGATOR
Kasr Al-Ainy Hospital, Faculty of Medicine, Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cairo University Hospitals
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
USGCQLBIIIPCNL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.